→ Germany’s CureVac has named a US CEO to help advance its work on mRNA. And not surprisingly he’ll be based in the Boston/Cambridge hub, where rival Moderna has been attracting attention — of all varieties. “As CEO of CureVac Inc., my goal will be to expand CureVac’s US business entity and to focus the corporate development efforts to grow our business globally,” said Daniel Menichella, who’s taking the post.
→ A few weeks after Foamix shares tanked on a Phase III disaster, with a split decision on efficacy in two late-stage acne studies, the biotech says it will gamble on a third trial in a bid to win an FDA approval.
→ Alkermes $ALKS has completed enrollment in its ENLIGHTEN-1 study, the first of two Phase III studies in the ENLIGHTEN clinical development program for ALKS 3831, an antipsychotic drug candidate for schizophrenia.
→ Shire says it will add 150 workers now that it has opened its new HQ offices in Dublin.
→ Shares of Sunesis Pharmaceuticals $SNSS slid 15% after the biotech reported that it is withdrawing its European application for vosaroxin, an AML drug, after regulators signaled that they were lining up a rejection.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.Free Subscription